Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Shares Outstanding (Weighted Average) (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Shares Outstanding (Weighted Average) for 4 consecutive years, with $319.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 27.82% to $319.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $319.7 million through Dec 2025, up 27.82% year-over-year, with the annual reading at $319.7 million for FY2025, 27.82% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $319.7 million in Q4 2025 for Taysha Gene Therapies, down from $353.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $353.3 million in Q3 2025 to a low of $38.2 million in Q1 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $168.0 million across 4 years, with a median of $173.7 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 265.55% in 2024 and later rose 16.46% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $44.0 million in 2022, then soared by 164.2% to $116.1 million in 2023, then skyrocketed by 115.41% to $250.1 million in 2024, then grew by 27.82% to $319.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for TSHA at $319.7 million in Q4 2025, $353.3 million in Q3 2025, and $298.0 million in Q2 2025.